Shares of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Analysts have set a 12-month consensus price target of $12.00 for the company and are anticipating that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also assigned Brainstorm Cell Therapeutics an industry rank of 113 out of 265 based on the ratings given to its competitors.
Several research analysts recently commented on BCLI shares. Maxim Group set a $9.00 target price on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a report on Monday, October 16th. ValuEngine downgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 21st.
A hedge fund recently raised its stake in Brainstorm Cell Therapeutics stock. Vanguard Group Inc. raised its stake in shares of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) by 2.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 657,101 shares of the biotechnology company’s stock after purchasing an additional 17,657 shares during the quarter. Vanguard Group Inc. owned 3.51% of Brainstorm Cell Therapeutics worth $2,733,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 13.08% of the company’s stock.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) traded up $0.89 during mid-day trading on Friday, hitting $3.92. 670,327 shares of the company traded hands, compared to its average volume of 134,687. The firm has a market cap of $55.77, a price-to-earnings ratio of -12.25 and a beta of 2.21. Brainstorm Cell Therapeutics has a 1-year low of $2.48 and a 1-year high of $5.18.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the company posted ($0.09) earnings per share. research analysts predict that Brainstorm Cell Therapeutics will post -0.37 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/13/analysts-anticipate-brainstorm-cell-therapeutics-inc-bcli-to-post-0-09-eps.html.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Get a free copy of the Zacks research report on Brainstorm Cell Therapeutics (BCLI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.